POMDOCTOR LIMITED (POM) expands AI-powered chronic disease data platform

Rhea-AI Filing Summary

POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, describes its strategy to build a healthcare data ecosystem to support AI-powered chronic disease management and predictive healthcare services. The company aggregates real-world data from wearable devices, remote patient monitoring, physician interactions, patient health management and healthcare payment-related activities.

Management emphasizes that high-quality real-world data is a core asset for AI platforms and expects continuous data flows to improve AI models and risk analysis. Industry research cited in the report projects strong global growth in real-world data markets, driven by electronic health records, telehealth, wearable devices and demand for personalized medicine.

Key Figures

Global RWD market 2026 (Precedence Research): US$2.15 billion Global RWD market 2035 (Precedence Research): US$7.11 billion Precedence Research CAGR: 14.23% +3 more

6 metrics

Global RWD market 2026 (Precedence Research) US$2.15 billion Projected global real-world data market size in 2026 per Precedence Research

Global RWD market 2035 (Precedence Research) US$7.11 billion Projected 2035 global real-world data market size with 14.23% CAGR from 2026

Precedence Research CAGR 14.23% Compound annual growth rate for global real-world data market from 2026 to 2035

Global RWD market 2026 (Coherent Market Insights) US$2.73 billion Projected global real-world data market size in 2026 per Coherent Market Insights

Global RWD market 2033 (Coherent Market Insights) US$7.08 billion Projected 2033 global real-world data market size with 14.6% CAGR

Coherent Market Insights CAGR 14.6% Compound annual growth rate for global real-world data market during 2026–2033 forecast period

Key Terms

real-world data, remote patient monitoring, compound annual growth rate, evidence-based medicine, +1 more

5 terms

real-world data medical

"RWD is emerging as a critical foundation for AI-enabled healthcare innovation"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

remote patient monitoring medical

"wearable technologies, remote patient monitoring (“RPM”) capabilities and physician resources"

Remote patient monitoring is the ongoing collection and transmission of a person’s health data (such as heart rate, blood sugar, or blood pressure) from home or another non-clinical setting to healthcare providers using connected devices and secure networks. For investors, it matters because it can reduce hospital visits, create steady service and device revenue, and change how care is paid for—think of it as a home security system for health that can lower costs and improve outcomes.

compound annual growth rate financial

"representing a compound annual growth rate (“CAGR”) of 14.23% from 2026 to 2035"

The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.

evidence-based medicine medical

"drivers cited include the increasing adoption of electronic health records, growing demand for evidence-based medicine"

Evidence-based medicine is the practice of evaluating medical treatments and products using well-designed scientific studies and data, rather than tradition or intuition. For investors, it matters because treatments supported by solid evidence are more likely to gain regulatory approval, wider medical adoption, reliable pricing and insurance coverage, and lower legal risk — think of it as choosing a product backed by a tested recipe rather than a guess.

predictive healthcare capabilities medical

"focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/15/2026 - 08:06 AM Accepted by SEC EDGAR 07/15/2026 - 08:05 AM Learn about SEC filing dates

FAQ

What strategic focus does POM (POMDOCTOR LIMITED) highlight in this 6-K?

POMDOCTOR LIMITED highlights a strategy to build a comprehensive healthcare data ecosystem supporting AI-powered chronic disease management, predictive healthcare services, and personalized, continuous care using real-world data, wearables, remote patient monitoring and physician resources.

How does POM (POMDOCTOR LIMITED) plan to use real-world data in its business?

POMDOCTOR LIMITED plans to aggregate real-world data from wearables, remote monitoring, physician interactions and payment insights to improve AI models, enhance health risk analysis and support more effective long-term chronic disease management services.

What market growth for real-world data does POM (POMDOCTOR LIMITED) cite?

The company cites research projecting the global real-world data market growing from about US$2.15 billion in 2026 to US$7.11 billion by 2035, and from US$2.73 billion in 2026 to US$7.08 billion by 2033, with mid-teens CAGR estimates.

Which technologies are central to POM (POMDOCTOR LIMITED)'s AI healthcare strategy?

Central technologies include artificial intelligence, wearable devices, remote patient monitoring, physician networks and healthcare payment systems, all integrated into a data-driven healthcare framework intended to deliver predictive, personalized and continuous healthcare management.

What does POM (POMDOCTOR LIMITED)'s CEO say about data in the future healthcare ecosystem?

CEO Zhenyang Shi states that data is a foundational asset of the future healthcare ecosystem and that collecting, analyzing and applying high-quality real-world data will be pivotal for predictive and personalized health management within the company’s AI-enabled platform.

What future priorities does POM (POMDOCTOR LIMITED) outline for its AI healthcare platform?

POMDOCTOR LIMITED plans to advance its healthcare data strategy, expand ecosystem partnerships and enhance technology capabilities as it pursues a vision of building a leading AI-enabled predictive healthcare infrastructure for patients, providers and other ecosystem participants.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2026

Commission file number: 001-42749

POMDOCTOR LIMITED

Yongxu Industrial Park
No.19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou 510000

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release—POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

POMDOCTOR LIMITED

/s/ Zhenyang Shi

Zhenyang Shi

Chairman and Chief Executive Officer

Date: July 15, 2026

2

Exhibit 99.1

POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities

GUANGZHOU, China, July 15, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its ongoing efforts to strengthen its healthcare data ecosystem, by leveraging real-world data (“RWD”), artificial intelligence (“AI”), wearable technologies, remote patient monitoring (“RPM”) capabilities and physician resources to enable more personalized, predictive and continuous healthcare management.

As digital transformation accelerates across healthcare systems worldwide, RWD is emerging as a critical foundation for AI-enabled healthcare innovation. Unlike traditional clinical datasets, RWD—generated through daily healthcare interactions, connected devices, patient monitoring and healthcare services—provides broader and richer insights into patient behaviors, disease progression and long-term health management needs. Market projections underscore the growing significance of RWD.

According to Precedence Research, the global RWD market is projected to grow from approximately US$2.15 billion in 2026 to approximately US$7.11 billion by 2035, representing a compound annual growth rate (“CAGR”) of 14.23% from 2026 to 2035. The report attributes this growth in part to the increasing adoption of RWD in clinical research and personalized healthcare solutions, alongside the expansion of telehealth services, increased reliance on remote patient data collection, and advancements in wearable and Internet of Things-enabled health devices.

Similarly, Coherent Market Insights estimates that the global RWD market will grow from approximately US$2.73 billion in 2026 to approximately US$7.08 billion by 2033, at a CAGR of 14.6% during the forecast period. Key drivers cited include the increasing adoption of electronic health records, growing demand for evidence-based medicine, regulatory support and continued advances in AI and data analytics. It also notes that demand for personalized medicine and chronic disease management is accelerating the adoption of RWD across healthcare systems.

Building a Healthcare Data Ecosystem to Power AI Capabilities

In response to these industry trends, Pomdoctor continues to develop a comprehensive healthcare data ecosystem designed to support AI-driven chronic disease management and predictive healthcare services.

The Company’s data-driven healthcare framework aggregates diverse RWD sources, including data generated from wearable devices, RPM-systems, physician interactions, patient health management activities and healthcare payment-related insights. This multidimensional data ecosystem aims to create a continuous feedback loop that strengthens AI analytics capabilities and supports the development of deeper personalized healthcare solutions.

Pomdoctor believes that high-quality healthcare data is a fundamental asset for the next generation of AI-powered healthcare platforms. As more healthcare interactions occur within the ecosystem, the resulting real-world insights are expected to continuously improve AI models, enhance health risk analysis capabilities and enable more effective long-term chronic disease management.

Management Commentary

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: “Data is a foundational asset of the future healthcare ecosystem. As AI reshapes healthcare delivery, the ability to collect, analyze and apply high-quality RWD will be pivotal to enabling predictive and personalized health management.

“At Pomdoctor, we are leveraging the extensive valuable data accumulated over years of operating our internet healthcare platform while continuing to build an integrated healthcare ecosystem that connects AI, wearables, RPM, physician networks and healthcare data assets. We believe this closed-loop ecosystem will continuously strengthen our AI capabilities, generate valuable real-world insights, and underpin sustained innovation.

“Looking ahead, we will advance our healthcare data strategy, expand our ecosystem partnerships, and enhance our technology capabilities as we pursue our vision of building a leading AI-enabled predictive healthcare infrastructure.”

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE-POMDOCTOR LIMITED ADVANCES HEALTHCARE DATA ASSET STRATEGY TO STREN 12.2 KB